About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Col1a1tm1(tetO-RNAi:Rps19)Karl
targeted mutation 1, Stefan Karlsson
MGI:5304754
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
 		Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae 		involves: 129S4/SvJae * C57BL/6 MGI:5304756
cx2
 		Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae 		involves: 129S4/SvJae * C57BL/6 MGI:5304757


Genotype
MGI:5304756
cx1
Allelic
Composition		 Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (160 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (30 available); any Gt(ROSA)26Sor mutation (942 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:179085 )
• most mice die within 2 months following doxycycline treatment

hematopoietic system
abnormal bone marrow cell morphology/development ( J:179085 )
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment
decreased bone marrow cell number ( J:179085 )
• by 10 days after doxycycline treatment
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment
decreased megakaryocyte cell number ( J:179085 )
• seven weeks after doxycycline treatment
abnormal proerythroblast morphology ( J:179085 )
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment
macrocytosis ( J:179085 )
• seven weeks after doxycycline treatment
thrombocytosis ( J:179085 )
• two weeks after doxycycline treatment
decreased erythrocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment
decreased neutrophil cell number ( J:179085 )
• seven weeks after doxycycline treatment
thrombocytopenia ( J:179085 )
• seven weeks after doxycycline treatment
decreased lymphocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment
reticulocytopenia ( J:179085 )
• two weeks after doxycycline treatment
abnormal bone marrow cell physiology ( J:179085 )
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment

growth/size/body
postnatal growth retardation ( J:179085 )
• following doxycycline treatment

digestive/alimentary system
abnormal large intestine morphology ( J:179085 )
• occasional dilated glands in the large intestine and colon

immune system
decreased neutrophil cell number ( J:179085 )
• seven weeks after doxycycline treatment
decreased lymphocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
Diamond-Blackfan anemia DOID:1339 OMIM:PS105650
 J:179085




Genotype
MGI:5304757
cx2
Allelic
Composition		 Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (160 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (30 available); any Gt(ROSA)26Sor mutation (942 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
mortality/aging ( J:179085 )
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment

hematopoietic system
abnormal bone marrow cell morphology/development ( J:179085 )
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment
decreased bone marrow cell number ( J:179085 )
• by 10 days after doxycycline treatment
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment
decreased megakaryocyte cell number ( J:179085 )
• seven weeks after doxycycline treatment
abnormal proerythroblast morphology ( J:179085 )
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment
macrocytosis ( J:179085 )
• seven weeks after doxycycline treatment
thrombocytosis ( J:179085 )
• two weeks after doxycycline treatment
decreased erythrocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment
decreased lymphocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment
reticulocytopenia ( J:179085 )
• two weeks after doxycycline treatment
abnormal bone marrow cell physiology ( J:179085 )
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment

immune system
decreased lymphocyte cell number ( J:179085 )
• two and seven weeks after doxycycline treatment

growth/size/body
postnatal growth retardation ( J:179085 )
• following doxycycline treatment
• less pronounced than in homozygous mice

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
Diamond-Blackfan anemia DOID:1339 OMIM:PS105650
 J:179085




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory